Table 2. Association of selected SNPs with HCV infection outcomes.
| a) SNPs associated with anti-HCV condition | ||||
| Genotype | Uninfected N(%) | Infected N(%) | OR (95% CI) a | P value a |
| rs1800454 | ||||
| GG | 594 (76.8) | 322 (69.4) | 1.00 | |
| AG | 158 (20.4) | 125 (26.9) | 1.60 (1.19–2.16) | 2.00×10–3 |
| AA | 21 (2.8) | 17 (3.7) | 1.48 (0.72–3.03) | 2.83×10–1 |
| Dominant | 1.59 (1.19–2.11) | 1.00×10–3 | ||
| Recessive | 1.32 (0.65–2.69) | 4.42×10–1 | ||
| Additive | 1.44 (1.13–1.82) | 3.00×10–3 | ||
| rs2071469 | ||||
| AA | 429 (55.5) | 300 (64.6) | 1.00 | |
| AG | 228 (29.5) | 129 (27.8) | 1.39 (1.03–1.88) | 3.10×10–2 |
| GG | 116 (15.0) | 35 (7.6) | 1.20 (0.76–1.87) | 4.33×10–1 |
| Dominant | 1.34 (1.01–1.79) | 4.00×10–2 | ||
| Recessive | 1.03 (0.67–1.57) | 9.02×10–1 | ||
| Additive | 1.17 (0.96–1.43) | 1.23×10–1 | ||
| b) SNPs associated with HCV chronicity | ||||
| Genotype | Resolver N(%) | Chronic N(%) | OR (95% CI) b | P value b |
| rs9277972 | ||||
| AA | 206 (83.7) | 164 (75.2) | 1.00 | |
| AT | 38 (15.4) | 50 (22.9) | 1.75 (1.08–2.85) | 2.40×10–2 |
| TT | 2 (0.9) | 4 (1.9) | 2.63 (0.46–15.14) | 2.78×10–1 |
| Dominant | 1.80 (1.12–2.88) | 1.60×10–2 | ||
| Recessive | 2.34 (0.41–13.42) | 3.39×10–1 | ||
| Additive | 1.72 (1.11–2.66) | 1.50×10–2 | ||
| rs3128935 | ||||
| TT | 175 (71.1) | 174 (79.8) | 1.00 | |
| CT | 63 (25.6) | 43 (19.7) | 0.69 (0.44–1.10) | 1.18×10–1 |
| CC | 8 (3.3) | 1 (0.5) | 0.11 (0.01–0.89) | 3.80×10–2 |
| Dominant | 0.62 (0.40–0.97) | 3.60×10–2 | ||
| Recessive | 0.12 (0.02–0.96) | 4.60×10–2 | ||
| Additive | 0.59 (0.40–0.89) | 1.20×10–2 | ||
a Logistic regression analyses adjusted for age, gender, and high-risk population.
b Logistic regression analyses adjusted for age, gender, high-risk population, and viral genotype.